A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Inclusion criteria

• Definite MS as determined by the McDonald criteria (Ann Neurol, July 2001) with a relapsing disease course.
• 2.EDSS 0.0 - 6.5 inclusive
• 18 to 55 years of age
• 1 or more T1 Gadolinium-enhancing lesions but no more than 15 lesions
• Able and willing to sign and date an informed consent form

Exclusion criteria

• Patients ever treated with Glatiramer Acetate or Mitoxantrone.
• Patients treated with interferons or IV immunoglobulins (IV Ig) in the previous 4 weeks prior to screening visits.
• Patients treated with methotrexate or azathioprine in the previous 6 months prior to screening visits.
• Patients ever treated with cyclophosphamide or Total Lymphoid Irradiation (TLI), or cladribine for injection or anthracenediones or anthracyclines, or prior mediastinal radiotherapy.
• Patients treated with intravenous or oral steroids within 28 days prior to initial MRI.
• Female patients must be non-pregnant, non-lactating, have a negative screening pregnancy test, and must use contraceptive methods deemed reliable by the investigator.
• Male patients and their partners must use contraceptive methods deemed reliable by the investigator
• LVEF < 50%
• Patients using catheters or Foley catheters
• Patients who have any other known significant systemic medical disease which may confound the evaluation of the study results such as: ALS, cervical spondylitic myelopathy, syphilis, arteritis, cerebellar syndrome (i.e., due to heredodegeneration), B12/folate deficiency, lyme disease, HTLV 1-myelopathy
• Patients with immune deficiency or other medical condition that would preclude treatment with Mitoxantrone or Glatiramer Acetate
• Abnormal screening blood tests exceeding any of the limits defined below:

Alanine transaminase (ALT) - twice the upper limit of normal Aspartate transaminase (AST) - twice the upper limit of normal Total white blood cell count < 2.3 x 103/uL Baseline neutrophil counts of < 1.5 x103/uL Platelet count < 80 x 103/uL Creatinine >1.5 mg/dL Prothrombin time greater than 150% upper limit of normal

• Patients with any medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the investigator.